RSC Med. Chem., 2023, Accepted Manuscript
DOI: 10.1039/D3MD00216K, Research ArticleYonghui Sun, Zimo Yang, Zhimin Zhang, Zhen Li, Liubin Guo, Hao Pan, Xin Luo, Dongzhou Liu, Yu Rao
Ibrutinib is a first-line drug for the treatment of B-cell malignancies. BTKC481S mutation has led to drug resistance during the clinical application. Herein, a novel BTK-targeting PROTAC molecule with better…
The content of this RSS Feed (c) The Royal Society of Chemistry
Design, synthesis, and evaluation of BTK-targeting PROTACs with optimized bioavailability in vitro and in vivo
